Key result
New antithrombotic drugs targeting novel biochemical pathways in platelet activation and coagulation offer the potential for more potent therapies with limited effects on hemostasis.
This review describes major advances in identifying new targets for more potent antithrombotic drugs with limited effects on hemostasis.
Warrants further research into novel antithrombotic pathways; leaves open whether benefits translate to reduced events without increased bleeding.
Thrombosis, both venous and arterial, is a major cause of morbidity and mortality worldwide. Consequently, there is an ongoing search for new antithrombotic drugs, particularly novel antiplatelet agents and anticoagulants. A better understanding of the biochemical pathways involved in platelet activation and coagulation and of the links between these systems and the impact of thrombosis on inflammation has led to the identification of new targets for antithrombotic drugs. This paper focuses on these new targets and new antiplatelet drugs and anticoagulants and describes the major advances in the continuing search for more potent antithrombotic drugs that have limited effects on hemostasis.
No takes yet. Share an insight, caveat, or question.
Gross et al. (2009) conducted a review in Thrombosis. New antithrombotic drugs was evaluated. New antithrombotic drugs targeting novel biochemical pathways in platelet activation and coagulation offer the potential for more potent therapies with limited effects on hemostasis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: